trending Market Intelligence /marketintelligence/en/news-insights/trending/oos_fXClMg8awWVCvWNzJQ2 content esgSubNav
In This List

Boston Scientific, BTG £3.3B merger cleared in 3 countries

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Boston Scientific, BTG £3.3B merger cleared in 3 countries

BTG PLC said its £3.3 billion acquisition by Boston Scientific Corp. received antitrust clearance in the U.S., Spain and Austria.

The proposed transaction was cleared by the U.S. Federal Trade Commission, Spanish regulator CNMC and the Federal Competition Authority of Austria.

The acquisition remains subject to closing conditions, including court approval, with the hearing scheduled on Aug. 15.

Marlborough, Mass.-based medical-device maker Boston Scientific announced in November 2018 that it was acquiring London's BTG, which develops and sells drugs for treating cancer and vascular diseases, for 840 pence per share through a scheme of arrangement.

The deal is expected to become effective Aug. 19. Upon completion, BTG's shares will be delisted from the London Stock Exchange on Aug. 20.